GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Cyclically Adjusted Price-to-FCF

BioLine Rx (BioLine Rx) Cyclically Adjusted Price-to-FCF : (As of May. 16, 2024)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioLine Rx Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioLine Rx's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cyclically Adjusted Price-to-FCF Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioLine Rx's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BioLine Rx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cyclically Adjusted Price-to-FCF falls into.



BioLine Rx Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioLine Rx's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BioLine Rx's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.069/129.4194*129.4194
=0.069

Current CPI (Dec. 2023) = 129.4194.

BioLine Rx Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -1.915 99.695 -2.486
201406 -1.935 100.560 -2.490
201409 -1.456 100.428 -1.876
201412 -2.086 99.070 -2.725
201503 -1.277 99.621 -1.659
201506 -1.433 100.684 -1.842
201509 -1.299 100.392 -1.675
201512 -0.937 99.792 -1.215
201603 -1.184 100.470 -1.525
201606 -0.878 101.688 -1.117
201609 -0.793 101.861 -1.008
201612 -1.043 101.863 -1.325
201703 -1.933 102.862 -2.432
201706 -0.676 103.349 -0.847
201709 -0.918 104.136 -1.141
201712 -0.966 104.011 -1.202
201803 -0.973 105.290 -1.196
201806 -0.881 106.317 -1.072
201809 -0.842 106.507 -1.023
201812 -2.018 105.998 -2.464
201903 -0.525 107.251 -0.634
201906 -0.667 108.070 -0.799
201909 -0.621 108.329 -0.742
201912 -0.517 108.420 -0.617
202003 -0.573 108.902 -0.681
202006 -0.379 108.767 -0.451
202009 -0.277 109.815 -0.326
202012 -0.257 109.897 -0.303
202103 -0.167 111.754 -0.193
202106 -0.153 114.631 -0.173
202109 -0.106 115.734 -0.119
202112 -0.117 117.630 -0.129
202203 -0.118 121.301 -0.126
202206 -0.133 125.017 -0.138
202209 -0.176 125.227 -0.182
202212 -0.096 125.222 -0.099
202303 -0.132 127.348 -0.134
202306 -0.159 128.729 -0.160
202309 -0.160 129.860 -0.159
202312 0.069 129.419 0.069

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioLine Rx  (NAS:BLRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioLine Rx Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Industry
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus